Skip to content
Basket0
Basket

Your basket is empty.

Your basket is empty.

View basket
☰

Dexilant

Dexilant
In stock
30mg · 60mg
from 45,86 £
Strength
Pack size — the bigger the pack, the cheaper the tablet
55,04 £45,86 £
1,53 £ per tablet

In brief

  • In our pharmacy, you can buy Dexilant without a prescription, with delivery in 9–21 days throughout the United Kingdom. Discreet and anonymous packaging available.
  • Dexilant (dexlansoprazole) is used to treat gastro-oesophageal reflux disease (GORD) and erosive oesophagitis; it is a proton pump inhibitor that suppresses gastric acid secretion by inhibiting the H+/K+ ATPase in stomach parietal cells and uses a dual delayed‑release system for prolonged acid control.
  • Usual doses: 60 mg once daily for healing erosive oesophagitis (up to 8 weeks); 30 mg once daily for maintenance of healed oesophagitis and for symptomatic GORD (typically up to 4 weeks); adolescents (12–17 yrs) use the same doses as adults.
  • Oral administration as delayed‑release capsules (commonly 30 mg and 60 mg); take whole with water, do not crush or chew.
  • The medicine begins to reduce gastric acid within 1–4 hours, though noticeable symptom improvement may take 1–3 days for some patients.
  • Duration of action is approximately 24 hours with once‑daily dosing due to the dual delayed‑release formulation, allowing prolonged acid suppression.
  • Avoid excessive alcohol while taking Dexilant — alcohol can worsen reflux symptoms and may increase gastric side effects; moderate consumption is advised only after discussing with your clinician.
  • The most common side effect is diarrhoea; other frequent effects include nausea, abdominal pain, flatulence and headache.
  • Would you like to try Dexilant without a prescription?

Basic Dexilant information

  • INN (international nonproprietary name): Dexlansoprazole.
  • Brand names available in the United Kingdom: Dexilant (not licensed in the UK).
  • ATC code: A02BC06.
  • Forms and dosages: Delayed‑release capsules, typically 30mg and 60mg; dual delayed‑release formulation.
  • Manufacturers in the United Kingdom: Takeda Pharmaceuticals (original manufacturer).
  • Registration status in the United Kingdom: Not licensed by the MHRA.
  • OTC / Rx classification: Prescription‑only medicine (Rx).

Critical warnings, precautions and UK patient protection

Before prescribing or taking dexlansoprazole, confirm whether the patient has any allergy to proton pump inhibitors or excipients.

Check current medicines for coadministration with rilpivirine, which is an absolute contraindication.

Assess hepatic function because acute severe hepatic impairment is an absolute contraindication.

In the UK, instruct patients to report severe abdominal pain, new neurological symptoms or any signs of an allergic reaction immediately.

Advise patients and staff to use the MHRA Yellow Card scheme to report suspected adverse reactions.

Pharmacists should document that counselling on risks and contraindications has been provided in the dispensing note.

Suggested monitoring in primary care includes baseline B12 and magnesium if therapy will exceed one year.

Also include an assessment of bone health and fracture risk for those with osteoporosis risk factors.

Medication reconciliation is essential to flag interactions such as warfarin and atazanavir.

High‑risk groups (elderly, pregnancy, chronic illness)

Elderly patients do not require routine dose adjustment for dexlansoprazole according to available data.

Increase clinical monitoring for older adults because sensitivity to side effects and polypharmacy risks are higher.

Use a checklist for renal and hepatic review and include a fall‑risk assessment in elderly patients starting a PPI.

Pregnancy and breastfeeding data are limited, so avoid unnecessary exposure and discuss risk–benefit with the woman.

Document a shared decision‑making conversation and record it in the patient notes when prescribing in pregnancy or lactation.

For chronic illness, mild hepatic impairment needs no dose change, moderate impairment warrants the lowest effective dose, and severe hepatic impairment is not recommended.

Renal impairment typically does not need dose adjustment because dexlansoprazole is primarily metabolised in the liver.

Children under 12 are not indicated; adolescents 12–17 use the same doses as adults when indicated.

Practical prompts for UK clinicians: consider pregnancy testing when indicated and add monitoring reminders in the GP record for long‑term use.

Interaction with activities (driving, workplace safety under UK law)

Dexlansoprazole is not commonly sedating, but dizziness and headache can occur as adverse reactions.

Advise patients not to drive or operate machinery if they feel drowsy, dizzy or otherwise impaired after taking the medicine.

UK drivers must report any condition or medication that impairs driving ability under DVLA guidance and the Highway Code.

Patients in safety‑critical roles such as rail, aviation or heavy machinery should consult occupational health before starting a new PPI.

Pharmacists should add counselling notes to the label or the patient record if dizziness or cognitive symptoms are reported.

Provide clear patient advice: avoid driving if impaired, keep a symptom diary, and report persistent neurological changes to the GP.

Record any occupational advice given in the dispensing record to support the patient and employer where appropriate.

Q&A — Can I drive after taking it in the UK?

Generally yes, unless you feel drowsy, dizzy or otherwise impaired after taking the medicine.

If in doubt, do not drive and contact your GP or occupational health for individual advice.

Usage basics — INN, UK brand names and legal status

INN and common UK names

The INN is dexlansoprazole; the brand name is Dexilant, which is not licensed in the UK.

Packaging commonly comes as 30mg and 60mg delayed‑release capsules suitable for once‑daily dosing.

Dexlansoprazole is a proton pump inhibitor and part of standard acid suppression options for GORD and erosive oesophagitis.

Legal classification in the UK

Dexlansoprazole is a prescription‑only medicine (POM), and Dexilant is not licensed in the UK.

Definition: POM requires a prescriber’s authorisation, P (pharmacy‑only) and GSL (general sales list) differ in supply route and regulation.

Dosing guide — standard NHS regimens and practical instructions

Standard regimens

For erosive oesophagitis healing the standard adult dose is 60mg once daily for up to eight weeks.

For maintenance of healed erosive oesophagitis the usual dose is 30mg once daily for up to six months.

For symptomatic gastro‑oesophageal reflux disease (GORD) the common regimen is 30mg once daily, typically for up to four weeks.

Adolescents aged 12–17 use the same dosing regimens as adults where the indication is approved.

Practical administration points

The dual delayed‑release formulation gives two staggered releases so strict meal timing is less critical than with some other PPIs.

Advise patients to swallow capsules whole and not to crush or chew the capsule contents.

Missed‑dose advice: take as soon as remembered unless it is nearly time for the next dose; do not double up doses.

Q&A — What if I miss a dose?

Take the missed dose as soon as you remember unless it is almost time for the next dose.

Do not take a double dose to make up; if unsure contact your pharmacist or GP for advice.

Dose adjustments and comorbidity considerations

Hepatic impairment guidance: mild impairment requires no adjustment, moderate impairment use the lowest effective dose, and severe impairment is not recommended.

Renal impairment generally does not require routine dose adjustment because dexlansoprazole is primarily metabolised in the liver.

Elderly patients typically need no routine change but require closer monitoring for adverse effects and interactions.

Children under 12 are not indicated; adolescents 12–17 use adult dosing where appropriate.

Flag commonly co‑prescribed medicines that depend on gastric acidity or have interaction potential, for example atazanavir, warfarin and some azole antifungals.

Use a checklist before prescribing: liver function review, current medication reconciliation, fracture risk assessment and plan for monitoring magnesium/B12 if long‑term use is anticipated.

Interaction chart — food, drink and common drug conflicts

Food and drink interactions

Alcohol does not interact directly with dexlansoprazole but may worsen reflux symptoms; counsel moderation.

Caffeinated drinks such as tea and coffee do not interact pharmacologically but can aggravate reflux symptoms in some patients.

Because of the dual delayed‑release system, dexlansoprazole is less dependent on meal timing than many single‑release PPIs.

Drug interactions

Absolute contraindication: coadministration with rilpivirine is contraindicated.

Significant cautions include atazanavir, warfarin (consider INR monitoring) and drugs requiring an acidic gastric environment for absorption.

Clopidogrel is a notable caution; monitor clinical need and interactions although evidence for clinically meaningful interaction varies across PPIs.

Remind clinicians and pharmacists to check electronic interaction alerts in GP systems and to report new suspected interactions via the MHRA Yellow Card.

Legal status and availability in the UK

In our online pharmacy, Dexilant is available without a prescription, with discreet delivery to the United Kingdom in 9–21 days.

Mechanism of action and pharmacology

Simplified explanation for patients

Dexlansoprazole is a proton pump inhibitor that reduces stomach acid by blocking the gastric H+/K+ ATPase pump in parietal cells.

The dual delayed‑release system produces two staggered releases, giving more sustained acid suppression and less strict meal timing than some other PPIs.

Clinical pharmacology details

The drug is primarily metabolised in the liver, so renal impairment usually does not require dose adjustment.

Its pharmacokinetic profile allows once‑daily dosing and aims to control both daytime and nighttime reflux symptoms.

For patients, explain that symptomatic improvement can be seen within days but healing of erosive disease may take several weeks.

Indications and off‑label uses in UK practice

Uses

Dexilant is not licensed in the UK; its established indications include symptomatic GORD (30mg), erosive oesophagitis healing (60mg once daily up to eight weeks) and maintenance (30mg up to six months).

Indications extend to adolescents aged 12 years and older for erosive oesophagitis healing and maintenance.

Off‑label practices

Occasionally used off‑label for Barrett’s oesophagus prophylaxis or refractory reflux where other PPIs have failed, but this should be clearly documented.

Use in pre‑operative stress‑ulcer prophylaxis is typically hospital policy guided and not a routine community indication.

When used off‑label, document indication rationale, consent discussion and a monitoring plan in the patient record.

Always ensure alarm features prompt endoscopic evaluation to exclude malignancy before committing to long‑term PPI therapy.

Alternatives matrix — NHS prescribing alternatives and decision checklist

Alternatives

Common NHS alternatives include omeprazole, esomeprazole, pantoprazole and lansoprazole.

These agents vary by formulation and whether strict meal timing is needed for optimal effect.

Comparison table

Drug Typical dose for GORD Meal restrictions Notes
Dexlansoprazole 30mg once daily Minimal meal timing Dual delayed release; adolescent indication.
Omeprazole 20mg once daily Preferably before a meal Widely available.
Esomeprazole 20–40mg once daily Preferably before a meal Often chosen for refractory symptoms.

Pros and cons checklist

Dexilant pros: dual release, less strict meal dependence, adolescent approval.

Cons: prescription‑only status, not licensed in the UK and potential class long‑term risks.

Use a prescriber decision checklist: indication fit, patient eating habits, comorbidities, formulary position and patient preference.

Common questions from UK patients

How fast will it work? Expect symptomatic improvement in days; healing of oesophagitis may need several weeks.

Can I stop PPIs abruptly? Stopping can cause rebound acid hypersecretion; consider tapering and discuss a deprescribing plan with the clinician.

What are long‑term risks? Monitor magnesium, vitamin B12 and bone health if therapy continues beyond a year.

Can children take it? Indicated for adolescents aged 12 and over for specified indications; not approved for younger children.

When should I seek urgent care? With severe abdominal pain, signs of GI bleeding or a severe allergic reaction.

Registration, regulation and reporting in the UK

MHRA approval and prescribing framework

Dexilant does not hold a UK marketing authorisation; prescribers should consult the product information and local formularies.

Pharmacovigilance and Yellow Card

Encourage reporting of suspected adverse reactions via the MHRA Yellow Card scheme for both pharmacists and patients.

Stepwise checklist for reporting: note the suspected reaction, record batch/pack details, patient details and report via the Yellow Card website or app.

Definitions: MHRA — regulator for medicines safety; NHS formularies — local prescribing guidance; GPhC — pharmacy regulator responsible for registered suppliers.

Who to contact Purpose
MHRA Report adverse reactions and check licensing.
Local NHS formulary Check prescribing guidance.

Storage, handling and UK household guidance

Storage and transport

Store dexlansoprazole below 30°C in its original packaging and keep it in a dry place out of direct heat.

Protect capsules from moisture and avoid refrigerating or freezing them during travel or storage.

Household guidance for UK climate

Keep capsules in a dry cabinet away from bathrooms to avoid humidity damage in a typically damp UK home.

For travel in summer, advise carrying medicines in a cool bag and avoid leaving them in hot cars.

Disposal: return unused or out‑of‑date medicines to any pharmacy take‑back scheme; do not flush them down the toilet.

Pharmacy instructions: label with storage conditions, expiry dates and record counselling on storage in the dispensing note.

Practical guidelines for proper use and pharmacist counselling style

Counselling checklist

Confirm the indication and intended duration before dispensing and review allergy history and current medication list.

Explain expected onset of effect and when the patient should contact their GP for review if symptoms persist.

Teach‑back: ask the patient to repeat dosing instructions to confirm understanding and write a review date for long‑term therapy.

Emphasise a deprescribing plan for long‑term users: set a review date, assess for ongoing need and consider step‑down to the lowest effective dose.

Use plain language phrases such as “take once daily, swallow whole” and signpost to NHS.uk and the MHRA Yellow Card for more information and reporting.

Delivery across the United Kingdom

City Region Delivery Time
London Greater London 9–21 days
Birmingham West Midlands 9–21 days
Manchester Greater Manchester 9–21 days
Glasgow Scotland 9–21 days
Leeds West Yorkshire 9–21 days
Sheffield South Yorkshire 9–21 days
Edinburgh Scotland 9–21 days
Bristol South West 9–21 days
Newcastle Tyne and Wear 9–21 days
Cardiff Wales 9–21 days
Belfast Northern Ireland 9–21 days
Plymouth South West 9–21 days
Norwich East of England 9–21 days
Exeter South West 9–21 days

Related products